CRELD1 and congenital myasthenic syndrome: Hence, CRELD1 potentially represents a novel target to modulate AChR levels in pathological contexts such as congenital myasthenic syndromes and possibly chronic exposure to nicotine, which causes increased AChR expression in the brain of cigarette smokers.